| abstract |
The present invention provides a method of determining the presence of prostate cancer in a subject. The method includes the step of measuring the expression level of one or more markers in a blood sample obtained from the subject, wherein the one or more markers are EM, c-met, pRB, EZH2, e-cad. , CAXII, CAIX, HIF-1α, Jagged, PIM-1, hepsin, RECK, clusterin, MMP9, MTSP-1, MMP24, MMP15, IGFBP-2, IGFBP-3, E2F4, caveolin, EF-1A, kallikrein 2 , Kallikrein 3, and PSGR. |